MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2025.09.008

Медицинская библиотека · Urologic oncology · 2025

An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer.

Peña Vanessa N, Wu Shan, Orikogbo Oluwaseun, Skupin Peyton A, Alameddine Mitchell, Yabes Jonathan G, Beichner Daniel, Olson Adam C, Davies Benjamin J, Sabik Lindsay M, Jacobs Bruce L

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

INTRODUCTION AND

OBJECTIVE

Stereotactic body radiation therapy (SBRT) is a novel form of radiotherapy for prostate cancer which uses ultra-hypofractionated radiation and allows for fewer treatment sessions compared to moderately hypofractionated regimens including intensity-modulated radiation therapy (IMRT). Recent studies have demonstrated comparable oncologic outcomes between SBRT and IMRT for intermediate-risk prostate cancer. We sought to compare the cost of SBRT and IMRT for intermediate-risk prostate cancer.

METHODS

We identified men over age 66 diagnosed with intermediate-risk prostate cancer who underwent IMRT or SBRT from 2008 to 2017 using the Surveillance, Epidemiology and End Results-Medicare Linked Database to compare per patient radiation-specific costs. Patients who received a therapeutic regimen, defined as ≥20 fractions of IMRT and ≥2 fractions of SBRT within 90 days, were included. Additionally, only patients treated in 1 locality was included to account for geographic variability in healthcare costs. Linear mixed-effects regression was used to compare per patient costs.

RESULTS

The final cohort included 934 IMRT patients and 237 SBRT patients. Our adjusted model showed the estimated total cost per patient was $20,130 for IMRT and $9,259 for SBRT (P < 0.01). Predictors of higher cost included residing in high-density areas, higher education levels, higher median household income, and earlier years of radiation treatment.

CONCLUSION

SBRT has significantly lower radiation-specific costs compared to IMRT for intermediate-risk prostate cancer. Our findings support the adoption of SBRT for the treatment of localized prostate cancer to lower healthcare costs while maintaining quality prostate cancer care.

Для цитирования: Peña Vanessa N, Wu Shan, Orikogbo Oluwaseun, Skupin Peyton A, Alameddine Mitchell, Yabes Jonathan G, Beichner Daniel, Olson Adam C, Davies Benjamin J, Sabik Lindsay M, Jacobs Bruce L. An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer.. Urologic oncology. 2025. DOI: 10.1016/j.urolonc.2025.09.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.